Veru Inc.

VERU | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.50

+$0.06 (+2.46%)

Sep 22, 2026, 2:31 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.46%

(1D)

Rating

Updated: Aug 20, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $40.21M

1D Range

2.42 2.51

52W Range

2.05 7.33

Valuation (TTM)

PE -4.07

PB 1.38

EV/EBITDA -0.67

Valuation (NTM)

Forward PE N/A

Forward PEG 1.37

Price Target $4

Cash Flow

FCF Yield -66.5%

SBC Adj. FCF Yield -70.4%

SBC Impact -5.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -101.9% | -64.2%

Dil EPS 3Y | 5Y 71.1% | 44.0%

FCF 3Y | 5Y 2.0% | 17.9%

Returns

ROA -36.8%

ROE -45.9%

ROIC -60.6%

Financial Health

Net Cash

$21.2M

Current Ratio 4.42

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to of...

Sector Healthcare

Industry Biotechnology

Employees 20

IPO Date Feb 10, 1999

Website www.verupharma.com

Fiscal Year October - September

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+60.00%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞